Table 1C. The main features of the included studies for the prognostic meta-analysis.
| Author | Year | Country | Ethnicity | Type | Sample | N | Age | Stage | Survival results | Follow-up(months) | HR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Kulda et al | 2010 | Czech | Caucasian | CRC | tissue | 46 | 62.8 | I-IV | DFS | 45.2 | 1.88(0.74,4.77) |
| Shibuya et al | 2010 | Japan | Asian | CRC | tissue | 156 | 65 | I-IV | DFS | 44 | 2.81(1.53,5.14) |
| Nielsen et al | 2011 | Denmark | Caucasian | CC | tissue | 129 | 70 | II | DFS | ≧60 | 1.28(1.06,1.55) |
| Nielsen et al | 2011 | Denmark | Caucasian | RC | tissue | 67 | 70 | II | DFS | ≧60 | 0.96(0.81,1.15) |
| Zhang et al | 2013 | China | Asian | CC | tissue | 138 | 65 | II | DFS | 66 | 1.98(0.95,4.15) |
| Zhang et al | 2013 | China | Asian | CC | tissue | 137 | 65 | II | DFS | 66 | 1.88(0.95,3.75) |
| Zhang et al | 2013 | China | Asian | CC | tissue | 460 | 65 | II | DFS | 66 | 1.79(1.22,2.62) |
| Menendez et al | 2013 | Spain | Caucasian | CRC | Serum | 102 | 71.6 | I-IV | DFS | 23 | 0.51(0.25,1.06) |
| Fukushima et al | 2015 | Japan | Asian | CRC | tissue | 306 | 65 | I-IV | DFS | 48 | 2.94(1.68,5.36) |
| Bullock et al | 2015 | UK | Caucasian | CRC | tissue | 50 | 72 | I-IV | DFS | 73 | 2.68(1.21,5.93) |
| Schetter et al | 2008 | America | Caucasian | CC | tissue | 71 | 64.4 | I-IV | OS | 80 | 2.70(1.30,5.50) |
| Schetter et al | 2008 | China | Asian | CC | tissue | 103 | 55.8 | I-IV | OS | 84.6 | 2.40(1.40,4.10) |
| Kulda et al | 2010 | Czech | Caucasian | CRC | tissue | 46 | 62.8 | I-IV | OS | 45.2 | 0.15(0.02,1.33) |
| Shibuya et al | 2010 | Japan | Asian | CRC | tissue | 156 | 65 | I-IV | OS | 44 | 2.69(1.70,4.25) |
| Nielsen et al | 2011 | Denmark | Caucasian | CC | tissue | 129 | 70 | II | OS | ≧60 | 1.17(1.02,1.34) |
| Nielsen et al | 2011 | Denmark | Caucasian | RC | tissue | 67 | 70 | II | OS | ≧60 | 0.97(0.83,1.13) |
| Faltejskova et al | 2012 | Czech | Caucasian | CRC | tissue | 44 | 67 | I-IV | OS | 84 | 1.81(0.56,5.83) |
| Frifeldt et al | 2012 | Denmark | Caucasian | CC | tissue | 520 | 71.9 | II | OS | 84 | 1.08(0.97,1.22) |
| Zhang et al | 2013 | China | Asian | CRC | tissue | 79 | 62.9 | I-IV | OS | 65.9 | 1.92(0.74,4.97) |
| Menendez et al | 2013 | Spain | Caucasian | CRC | Serum | 102 | 71.6 | I-IV | OS | 23 | 0.50(0.25,1.02) |
| Liu et al | 2013 | China | Asian | CRC | Serum | 166 | 57.09 | I-IV | OS | 36.4 | 1.58(0.77-3.21) |
| Toiyama et al | 2013 | Japan | Asian | CRC | tissue | 153 | 67.5 | I-IV | OS | 44 | 0.59(0.21,1.63) |
| Toiyama et al | 2013 | Japan | Asian | CRC | Serum | 153 | 67.5 | I-IV | OS | 44 | 4.12(1.10,15.4) |
| Chen et al | 2013 | China | Asian | CRC | tissue | 195 | 66 | I-IV | OS | 60 | 2.56(1.43,4.57) |
| Bovell et al | 2013 | America | Caucasian | CRC | tissue | 55 | 65 | IV | OS | 198 | 3.25(1.37,7.72) |
| Oue et al | 2014 | Japan | Asian | CC | tissue | 87 | 63 | II-III | OS | 54 | 3.13(1.20,8.17) |
| Oue et al | 2014 | Genmany | Caucasian | CC | tissue | 145 | 70 | II | OS | 51.6 | 2.65(1.06,6.66) |
| Hansen et al | 2014 | Denmark | Caucasian | CC | tissue | 554 | 74 | II-IV | OS | 60 | 1.08(0.89,1.30) |
| Fukushima et al | 2015 | Japan | Asian | CRC | tissue | 306 | 65 | I-IV | OS | 48 | 2.88(1.70,5.08) |
| Bullock et al | 2015 | UK | Caucasian | CRC | tissue | 50 | 72 | I-IV | OS | 73 | 2.47(1.19,5.55) |
| Kang et al | 2015 | Korea | Asian | CC | tissue | 173 | 63 | II-III | OS | 80 | 0.43(0.14,1.27) |
| Kang et al | 2015 | Korea | Asian | RC | tissue | 104 | 63 | II-III | OS | 80 | 2.05(0.56,7.51) |
AUC: area under the curve; Se: sensitivity; Sp: specificity; QUADAS: quality assessment of diagnostic accuracy studies. This scoring system comprises seven questions, requiring an answer of “yes,” “no,” or “unclear.”
An answer of “yes” gets a score of 1, while an answer of “no” or “unclear” gets a score of 0; miR panels: miR-18a, miR-20a, miR-21, miR-29a, miR-92a, miR-106b, miR-133a, miR-143, miR-145, miR-342-3p, miR-532-3p, miR-181b; NA: not available; N: number of participants; DFS: disease-free survival; OS: overall survival; HR: hazard ratio; 95% CI: 95% confidence interval.